Humacyte Secures New Patent for Engineered Tissues
The U.S. Patent and Trademark Office issued a new patent covering manufacturing, storage, and shipping for Humacyte's medical products.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Does extensive patent protection for medical manufacturing technologies serve the public interest?
Humacyte has received U.S. Patent No. 12,742,144, covering the company's proprietary methods for manufacturing and transporting its bioengineered tissue constructs. This intellectual property protection extends until 2043 and covers critical processes for products grown using human cells.
Why it matters
The patent strengthens Humacyte's intellectual property portfolio by securing the proprietary technologies required to handle its tissue products from production to surgical implantation. This protection safeguards the company's specialized shipping and containment methods as it expands its medical offerings.
Humacyte operates an 83,000 square foot bioprocessing facility in Durham, North Carolina, utilizing proprietary LUNA200 production equipment. Products like the ATEV are grown in sealed bioreactor bags to maintain sterility until the moment of surgery.
The players
Humacyte
Humacyte is a biotech company focused on developing universally implantable bioengineered human tissues.
United States Patent and Trademark Office
The United States Patent and Trademark Office is the federal agency responsible for granting U.S. patents and registering trademarks.
The details
The patent covers the complex systems and devices necessary for maintaining engineered tissue constructs during transport. These methods ensure that bioengineered vessels remain stable while being shipped from the Durham facility to healthcare providers.
Timeline
December 2024: The FDA approved the Humacyte acellular tissue engineered vessel for vascular trauma.
October 28, 2026: The United States Patent and Trademark Office issued the new patent.
2043: The new patent protection is scheduled to expire.
The Tech Race
This patent secures critical manufacturing and logistical infrastructure, positioning Humacyte to better compete in the growing market for bioengineered materials. It marks a shift toward industrializing living tissue production by standardizing the storage and shipping processes once limited to laboratory environments.
For patients, this patent ensures the security and stability of advanced medical implants as they move from the production facility to the operating room. Reliable shipping processes are essential for maintaining the integrity of these tissues, which directly impacts the safety and efficacy of final medical treatments.
The takeaway
Securing long-term intellectual property rights is a vital milestone for biotech firms scaling the production of complex living therapies. This patent effectively locks in Humacyte's logistical advantages through the early 2040s.
What happens next
Humacyte plans to submit a supplemental Biologics License Application (BLA) for its dialysis access products by the end of 2026.
Further reading
Learn more about the latest innovations in the field on the Biotech section page.
Source note: This article includes information reported by The Manila times.
Live Poll
Does extensive patent protection for medical manufacturing technologies serve the public interest?
